Innate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Down 94.0% in January

Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a large decline in short interest in January. As of January 15th, there was short interest totalling 500 shares, a decline of 94.0% from the December 31st total of 8,400 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 5.0 days.

Innate Pharma Stock Performance

Shares of IPHYF remained flat at $2.90 during mid-day trading on Friday. The firm's 50-day simple moving average is $2.42 and its two-hundred day simple moving average is $2.21. Innate Pharma has a twelve month low of $1.28 and a twelve month high of $2.90.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.